Comorbidity characteristics of overall sample and the study cohort.
| Characteristics | Overall Sample, n = 310,695 | Study Cohort without SU Test Postindex Filled Allopurinol Prescription, n = 263,623 | Study Cohort with At Least 1 SU Test Postindex Filled Allopurinol Prescription, n = 47,072 |
|---|---|---|---|
| Deyo-Charlson index comorbidities | |||
| Myocardial infarction | 9841 (3.2) | 8063 (3.1) | 1778 (3.8) |
| Coronary heart disease | 38,989 (12.5) | 32,111 (12.2) | 6878 (14.6) |
| Peripheral vascular disease | 25,655 (8.3) | 21,266 (8.1) | 4389 (9.3) |
| Cerebrovascular disease | 23,948 (7.7) | 20,012 (7.6) | 3936 (8.4) |
| Dementia | 1693 (0.5) | 1447 (0.6) | 246 (0.5) |
| Chronic pulmonary disease | 52,886 (17.0) | 44,339 (16.8) | 8547 (18.2) |
| Rheumatologic disease | 5052 (1.6) | 3993 (1.5) | 1059 (2.3) |
| Peptic ulcer disease | 4780 (1.5) | 4050 (1.5) | 730 (1.6) |
| Mild liver disease | 2435 (0.8) | 2004 (0.8) | 431 (0.9) |
| Diabetes | 108,283 (34.9) | 90,891 (34.5) | 17,392 (37.0) |
| Diabetes with complications | 27,629 (8.9) | 22,561 (8.6) | 5068 (10.8) |
| Paraplegia | 855 (0.3) | 697 (0.3) | 158 (0.3) |
| Renal disease | 20,556 (6.6) | 16,112 (6.1) | 4444 (9.4) |
| Malignancy | 34,221 (11.0) | 28,532 (10.8) | 5689 (12.1) |
| Severe liver disease | 830 (0.3) | 701 (0.3) | 129 (0.3) |
| Malignant neoplasm without specification of site | 1631 (0.5) | 1350 (0.5) | 281 (0.6) |
| AIDS | 912 (0.3) | 705 (0.3) | 207 (0.4) |
| Cancer | 34,443 (11.1) | 28,721 (10.9) | 5722 (12.2) |
| Hepatic coma | 175 (0.1) | 145 (0.1) | 30 (0.1) |
| Deyo-Charlson comorbidity index score, mean (SD) | 1.4 (1.6) | 1.3 (1.6) | 1.6 (1.7) |
Data are n (%) unless otherwise indicated. Bold text denotes Deyo-Charlson comorbidities that were statistically significant between the 2 groups with an unadjusted p value of < 0.05. SU: serum urate.